Renal effects of indoprofen in rhesus monkeys.

Arzneimittelforschung

Published: December 1982

The non-steroidal anti-inflammatory analgesic alpha-[4-(1-oxo-2-iso-indolinyl)-phenyl]propionic acid (indoprofen) was given p.o. in gelatin capsules to six groups of six Rhesus monkeys (three males and three females/group) for 15 months. Group I (five males and five females) served as control and was given empty gelatin capsules. The following daily doses were used: Group 2--20 mg/kg b.i.d.; Group 3--40 mg/kg q.d.; Group 4--30 mg/kg b.i.d.; Group 5--60 mg/kg q.d.; Group 6--40 mg/kg b.i.d. and Group 7--80 mg/kg q.d. Except for some elevated blood urea nitrogen levels after 12 months in the animals of Group 7, no changes in clinical function test values, absolute and relative kidney weights or renal gross abnormalities were found. The renal papillae and pelves were normal and not affected in all monkeys. The microscopic examination revealed a focal chronic interestitial nephritis in some of the monkeys. In the survivors the incidence of this disease increased from one out of ten control animals to three out of five monkeys in Group 7 (80 mg/kg/d). However, this quantal, statistically significant difference became biologically irrelevant and no longer statistically significant when these microscopic changes were quantified. The most severe case was seen in the control animal and the least pronounced in monkeys having received 80 mg/kg/d. When these cases of interstitial nephritis were further evaluated using a multifactorial point sampling procedure, no significant quantitative changes in renal tissue components, indicative of analgesic-induced nephropathy, were detectable.

Download full-text PDF

Source

Publication Analysis

Top Keywords

mg/kg bid
12
bid group
12
group
9
rhesus monkeys
8
gelatin capsules
8
mg/kg group
8
monkeys
6
mg/kg
6
renal
4
renal effects
4

Similar Publications

Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival.

J Control Release

January 2025

Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Minas Gerais, Brazil. Electronic address:

A huge challenge after the emergence of COVID-19 has been the discovery of effective antiviral drugs. Although remdesivir (RDV) emerged as one of the most promising drugs, its pharmaceutical formulation Veklury® is limited by moderate efficacy, high toxicity and need for parenteral administration. The aim of the present work was to develop a liposomal formulation of RDV for pulmonary administration and evaluate its efficacy in models of COVID-19.

View Article and Find Full Text PDF

Discovery of an Orally Efficacious Pyrazolo[3,4-]pyrimidine Benzoxaborole as a Potent Inhibitor of .

J Med Chem

January 2025

Department of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, Missouri 63103, United States.

Cryptosporidiosis is a diarrheal disease caused by the parasite resulting in over 100,000 deaths annually. Here, we present a structure-activity relationship study of the benzoic acid position (R) of pyrazolo[3,4-]pyrimidine lead SLU-2815 (), an inhibitor of parasite phosphodiesterase PDE1, resulting in the discovery of benzoxaborole SLU-10906 () as a benzoic acid bioisostere. Benzoxaborole is 10-fold more potent than against the parasite in a cell-based infection model (EC = 0.

View Article and Find Full Text PDF

Despite the end of COVID-19 pandemic, only intravenous remdesivir was approved for treatment of vulnerable pediatric populations. Molnupiravir is effective against viruses beyond SARS-CoV-2 and is orally administrable without CYP-interaction liabilities but has a burden of potential bone or cartilage toxicity, observed at doses exceeding 500 mg/kg/day in rats. Especially, activity of molnupiravir against viruses, such as Ebola, with high fatality rates and no treatment option warrants the exploration of potentially effective but safe doses for pediatric populations, i.

View Article and Find Full Text PDF

Despite the success of first, second, and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer with classical EGFR mutations (L858R or Exon 19 deletions), disease progression occurs due to the acquisition of T790M and C797S resistance. Herein, we report a physics-based computationally driven lead identification approach that identified structurally unique imidazo[3.2-]pyrazoles as reversible and wild-type-sparing EGFR TKIs of classical mutations bearing both T790M and C797S.

View Article and Find Full Text PDF

Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer (mCRC). This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and oxaliplatin)/modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody) in untreated unresectable mCRC. Induction treatment included capecitabine 1000 mg/m bid D2-8 and D16-22, oxaliplatin 85 mg/m D1, irinotecan 150 mg/m D15, and bevacizumab 5 mg/kg D1 and 15 for 28-day cycles (up to six cycles).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!